Related Experiment Video
Updated: Jun 3, 2025

08:55
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
16.1K
Early identification of potentially reversible cancer cachexia using explainable machine learning driven by body
Liangyu Yin1, Na Li2, Xin Lin2
1Department of Nephrology, Chongqing Key Laboratory of Prevention and Treatment of Kidney Disease, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
The American Journal of Clinical Nutrition
|January 9, 2025
Summary
Machine learning can now identify potentially reversible cancer cachexia (PRCC) using simple body weight changes. This model aids in early detection and improved management for better patient outcomes.
Area of Science:
- Oncology
- Machine Learning
- Biostatistics
Background:
- Cancer cachexia is linked to poor patient outcomes and poses clinical challenges.
- Early identification of reversible cachexia is crucial for effective management.
Purpose of the Study:
- To develop and validate a machine learning (ML) model for identifying potentially reversible cancer cachexia (PRCC).
Main Methods:
- A multicenter cohort study retrospectively diagnosed cachexia using Fearon's framework.
- ML models were trained on patient admission body weight dynamics to predict PRCC.
- The optimal model was evaluated for interpretability, clinical usefulness, and external validation.
Main Results:
- The ML model achieved high performance in predicting PRCC (AUC 0.887 in test set, 0.863 in external validation).
- Weight change in the month preceding baseline was the most impactful predictor.
- Potentially reversible cancer cachexia (PRCC) was identified in 52.6% of patients, with breast cancer showing the highest rate.
Conclusions:
- An explainable ML model effectively identifies PRCC using accessible body weight dynamics.
- This approach shows promise for improving cancer cachexia management and patient outcomes.

